Headquartered in Pittsburgh, USA, Neoolife is a privately held, pre-clinical Bio-MedTech company with a presence in Europe. We focus on polymeric tissue-engineered Biomimetic Heart Valves (BMHV) and tissue-engineered Biomimetic CardioVascular Patches (BMCP) for percutaneous and surgical applications enabling endogenous in-situ tissue regeneration. Neoolife is also proposing original percutaneous solutions. Neoolife Transcatheter Tricuspid Valve Replacement (TTVR) system is the first device worldwide having an innovative, non-animal derived tissue-engineered Biomimetic Heart Valve with extended durability and resistance to thrombosis and calcification.
Caution: The Neoolife device is in the early R&D development phase and is NOT available for sale in any region of the world.